Worldwide Cancer Research

Lynparza is now the primary PARP inhibitor to claim a win that, as ASCO put it, “could change the standard of care in adjuvant systemic therapy” for germline BRCA1/2-mutated, HER2-adverse early breast cancer. With the primary and solely accredited focused …